4967 Stock Overview
Engages in the manufacture and sale of OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Kobayashi Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥5,962.00 |
| 52 Week High | JP¥6,866.00 |
| 52 Week Low | JP¥4,700.00 |
| Beta | 0.25 |
| 1 Month Change | 4.07% |
| 3 Month Change | 4.96% |
| 1 Year Change | -10.79% |
| 3 Year Change | -33.98% |
| 5 Year Change | -36.10% |
| Change since IPO | 235.36% |
Recent News & Updates
Recent updates
Calculating The Intrinsic Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)
Nov 27
Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear
Aug 21Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely
Aug 04Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking
Apr 21Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)
Apr 03Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)
Feb 27Shareholder Returns
| 4967 | JP Personal Products | JP Market | |
|---|---|---|---|
| 7D | -0.6% | -1.7% | -1.5% |
| 1Y | -10.8% | -10.5% | 13.7% |
Return vs Industry: 4967 matched the JP Personal Products industry which returned -10.5% over the past year.
Return vs Market: 4967 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 4967 volatility | |
|---|---|
| 4967 Average Weekly Movement | 3.2% |
| Personal Products Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4967 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4967's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 2,647 | Satoshi Yamane | www.kobayashi.co.jp |
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese medicine; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air freshener, lens cleaner, cooling gel sheets, and oral hygiene products. It also manufactures and sells pharmaceuticals, cosmetics, and health foods; and manufactures and sells synthetic resin products; markets nutritional supplements and skin care products through mail orders; and sells skincare products, daily necessities, and health foods, as well as manufactures body warmers.
Kobayashi Pharmaceutical Co., Ltd. Fundamentals Summary
| 4967 fundamental statistics | |
|---|---|
| Market cap | JP¥443.21b |
| Earnings (TTM) | JP¥10.18b |
| Revenue (TTM) | JP¥168.80b |
43.5x
P/E Ratio2.6x
P/S RatioIs 4967 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4967 income statement (TTM) | |
|---|---|
| Revenue | JP¥168.80b |
| Cost of Revenue | JP¥77.83b |
| Gross Profit | JP¥90.97b |
| Other Expenses | JP¥80.78b |
| Earnings | JP¥10.18b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 136.99 |
| Gross Margin | 53.89% |
| Net Profit Margin | 6.03% |
| Debt/Equity Ratio | 0% |
How did 4967 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield74%
Payout RatioDoes 4967 pay a reliable dividends?
See 4967 dividend history and benchmarks| Kobayashi Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Mar 07 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 75 days |
Does 4967 pay a reliable dividends?
See 4967 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:56 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kobayashi Pharmaceutical Co., Ltd. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitsuko Miyasako | Barclays |
| Ritsuko Tsunoda | BofA Global Research |
| Daisuke Yamaguchi | Citigroup Global Markets Japan Inc. |